# Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy

> **NCT07746882** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 680 (estimated)

## Conditions studied

- Stroke
- Acute Ischemic Stroke

## Interventions

- **DRUG:** Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT07746882
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-11-30
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746882, "Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*